A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus

作者：Riffault Sabine^*; Meyer Gilles; Deplanche Martine; Dubuquoy Catherine; Durand Guillaume; Soulestin Marion; Castagne Nathalie; Bernard Julie; Bernardet Philippe; Dubosclard Virginie; Bernex Florence; Petit Camurdan Agnes; Deville Sebastien; Schwartz Cornil Isabelle; Eleouet Jean Francois

来源：Vaccine, 2010, 28(21): 3722-3734.

DOI：10.1016/j.vaccine.2010.03.008

• Respiratory syncytial virus
• Nucleoprotein
• Calves
• Bronchopneumonia

Human and bovine respiratory syncytial viruses (HRSV and BRSV) are two closely related, worldwide prevalent viruses that are the leading cause of severe airway disease in children and calves, respectively. Efficacy of commercial bovine vaccines needs improvement and no human vaccine is licensed yet. We reported that nasal vaccination with the HRSV nucleoprotein produced as recombinant ring-shaped nanoparticles (N(SRS)) protects mice against a viral challenge with HRSV. The aim of this work was to evaluate this new vaccine that uses a conserved viral antigen, in calves, natural hosts for BRSV. Calves, free of colostral or natural anti-BRSV antibodies, were vaccinated with N(SRS) either intramuscularly, or both intramuscularly and intranasally using Montanide (TM) ISA71 and IMS4132 as adjuvants and challenged with BRSV. All vaccinated calves developed anti-N antibodies in blood and nasal secretions and N-specific cellular immunity in local lymph nodes. Clinical monitoring post-challenge demonstrated moderate respiratory pathology with local lung tissue consolidations for the non-vaccinated calves that were significantly reduced in the vaccinated calves. Vaccinated calves had lower viral loads than the non-vaccinated control calves. Thus N(SRS) vaccination in calves provided cross-protective immunity against BRSV infection without adverse inflammatory reaction.

• 出版日期2010-5-7